X

Drug Profile

iSCIB 1+

Alternative Names: iSCIB1+

Latest Information Update: 24 Jul 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Scancell
Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Cancer; Malignant melanoma

Most Recent Events

10 Jul 2023 Scancell plans a registration clinical trial for Cancer (Parenteral), in the second half of 2024
10 Jul 2023 Scancell plans to initiate a similar double checkpoint cohort of the phase II SCOPE study with iSCIB 1+ in Cancer (Parenteral), before the end of 2023
10 Jul 2023 Scancell has patent protection for AvidiMab™ technology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com